Literature DB >> 5630229

Separation and characterization of soluble adenovirus type 9 components.

E Norrby, B Nyberg, P Skaaret, A Lengyel.   

Abstract

Four different soluble components of adenovirus type 9 (Rosen's group II) were identified. These were a complete hemagglutinin (HA), an incomplete HA, components carrying group-specific complement-fixing (CF) antigen, and components identified only by their hemagglutination-inhibition (HI) antibody consuming capacity and antigen activity in CF tests with an antiserum against complete HA. The complete HA sedimented relatively rapidly. It was composed of 12 pentons (vertex capsomers plus projections) aggregated into the form of a pentagonal dodecahedron. The length of the projections was about 12 to 13 mmu. Thus they appeared longer than the corresponding structures of types 3 and 11, but shorter than those of types 4 and 5. The rate of sedimentation of complete HA of type 9 was intermediate to those of the complete HA of types 3 and 11. The incomplete HA sedimented together with components carrying group-specific CF antigen, but could be separated from those by anion-exchange chromatography. Two different antigens were present in incomplete HA. One could absorb a group-specific hemagglutination-enhancing antibody, and was sensitive to treatment with trypsin. The other antigen could absorb the type-specific HI antibody and was not destroyed by trypsin. In addition to the incomplete HA, a separate population of more slowly sedimenting components showed a capacity to absorb HI antibody. These components could also be identified in CF tests when an antiserum against complete HA was applied. The incomplete HA, group-specific CF antigen, and slowly sedimenting HI antibody absorbing components are suggested to represent isolated penton, hexon, and fiber components, respectively.

Entities:  

Mesh:

Substances:

Year:  1967        PMID: 5630229      PMCID: PMC375396     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  20 in total

1.  Study of adenovirus antigens by immunoelectrophoresis.

Authors:  H G PEREIRA; A C ALLISON; C P FARTHING
Journal:  Nature       Date:  1959-03-28       Impact factor: 49.962

2.  Impairment of viral haemagglutination of red cells after treatment with formalin.

Authors:  F E BUCKLAND
Journal:  Nature       Date:  1959-05-02       Impact factor: 49.962

3.  Study of adenovirus antigens fractionated by chromatography on DEAE-cellulose.

Authors:  H G KLEMPERER; H G PEREIRA
Journal:  Virology       Date:  1959-12       Impact factor: 3.616

4.  Modification of erythrocyte receptors by a factor in adenovirus suspensions.

Authors:  J A KASEL; W P ROWE; J L NEMES
Journal:  Virology       Date:  1960-03       Impact factor: 3.616

5.  Complement fixation with Brunhilde and Lansing poliomyelitis viruses propagated in tissue culture.

Authors:  A SVEDMYR; J F ENDERS; A HOLLOWAY
Journal:  Proc Soc Exp Biol Med       Date:  1952-02

6.  The relationship between soluble antigens and the virion of adenovirus type 3. 3. Immunological identification of fiber antigen and isolated vertex capsomer antigen.

Authors:  E Norrby; P Skaaret
Journal:  Virology       Date:  1967-07       Impact factor: 3.616

7.  Ultrastructure of soluble antigens and the virion of adenovirus type 4.

Authors:  G Wadell; E Norrby; U Schönning
Journal:  Arch Gesamte Virusforsch       Date:  1967

8.  [The electrophoretic separability of adenovirus components in a density gradient].

Authors:  W A Schmidt
Journal:  Arch Gesamte Virusforsch       Date:  1967

9.  Soluble components of adenovirus type 4.

Authors:  E Norrby; G Wadell
Journal:  Virology       Date:  1967-04       Impact factor: 3.616

10.  The relationship between the soluble antigens and the virion of adenovirus type 3. II. Identification and characterization of an incomplete hemagglutinin.

Authors:  E Norrby
Journal:  Virology       Date:  1966-12       Impact factor: 3.616

View more
  18 in total

1.  Association of endonuclease activity with serotypes belonging to the three subgroups of human adenoviruses.

Authors:  R G Marusyk; A R Morgan; G Wadell
Journal:  J Virol       Date:  1975-08       Impact factor: 5.103

2.  1. Alternative splicing of viral receptors: A review of the diverse morphologies and physiologies of adenoviral receptors.

Authors:  Katherine J D A Excoffon; Jonathan R Bowers; Priyanka Sharma
Journal:  Recent Res Dev Virol       Date:  2014

3.  Thin-layer chromatography of lipids in adenovirus-treated human erythrocytes.

Authors:  A Lengyel; M Klembala; I Nász
Journal:  Arch Gesamte Virusforsch       Date:  1973

4.  [Dodecon, the soluble hemagglutinin present in all adenovirus types of subgroup II].

Authors:  I T Liem; I Kron; R Wigand
Journal:  Arch Gesamte Virusforsch       Date:  1971

5.  Immunological relationships between hexons of certain human adenoviruses.

Authors:  E Norrby; G Wadell
Journal:  J Virol       Date:  1969-11       Impact factor: 5.103

6.  Capsid mosaics of intermediate strains of human adenoviruses.

Authors:  E Norrby
Journal:  J Virol       Date:  1969-11       Impact factor: 5.103

7.  [The inactivation of adenovirus components by means of physical and chemical agents].

Authors:  N Ratanakrong; R Wigand
Journal:  Z Med Mikrobiol Immunol       Date:  1968

8.  [Type-specific antigens of adenovirus].

Authors:  W Meiser; J Lange; D Loytved; R Wigand
Journal:  Arch Gesamte Virusforsch       Date:  1969

9.  The soluble hemagglutinins of adenoviruses belonging to Rosen's subgroup 3. I. The rapidly sedimenting hemagglutinin.

Authors:  G Wadell; E Norrby; P Skaaret
Journal:  Arch Gesamte Virusforsch       Date:  1969

10.  The cell adhesion molecule "CAR" and sialic acid on human erythrocytes influence adenovirus in vivo biodistribution.

Authors:  Elena Seiradake; Daniel Henaff; Harald Wodrich; Olivier Billet; Matthieu Perreau; Claire Hippert; Franck Mennechet; Guy Schoehn; Hugues Lortat-Jacob; Hanna Dreja; Sandy Ibanes; Vasiliki Kalatzis; Jennifer P Wang; Robert W Finberg; Stephen Cusack; Eric J Kremer
Journal:  PLoS Pathog       Date:  2009-01-02       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.